Amicus speeds up its FDA timeline; Salix execs pocket millions after accounting scandal;

@FierceBiotech: J&J stays mum about cash, but biotech buyout is a landmark win for Index fund. Story | Follow @FierceBiotech

@JohnCFierce: Crohn's expert flags blockbuster potential--and frets--of Celgene's mongersen. News | Follow @JohnCFierce

@DamianFierce: Today begins the round of 64 in FierceMadness, a pointless & absurd tournament of drug names. More | Follow @DamianFierce

> Amicus Therapeutics ($FOLD) accelerated its plans to submit its lead drug for regulatory approval following some positive discussions with U.S. and European regulators. The company now plans file migalastat, a treatment for Fabry disease, in the second quarter. More

> Despite a value-destroying accounting scandal, two former Salix Pharmaceuticals ($SLXP) execs are walking away with $46 million thanks to Valeant Pharmaceuticals' ($VRX) pending $11.1 billion acquisition of the company, Bloomberg reports. News

> Daiichi Sankyo is paying $200 million up front to partner up on AstraZeneca ($AZN) and Nektar Therapeutics' ($NKTR) recently approved constipation drug Movantik, promising up to $625 million more depending on sales. Story

Medical Device News

@FierceMedDev: ICYMI: Vivo Capital doubles down to close $750M US-China healthcare fund. Story | Follow @FierceMedDev

@VarunSaxena2: Medtronic's stent for peripheral artery disease wins expanded indication from FDA. Story | Follow @VarunSaxena2

@EmilyWFierce: Changes in public's perceptions of risk contributes to spread of infectious diseases, says NIAID director. More from The Atlantic | Follow @EmilyWFierce

> Boston Scientific subsidiary hit with $50M gender discrimination suit. Report

> Canon BioMedical makes first move with rapid DNA, drug metabolism diagnostic startup. Story

> Medtronic's stent for peripheral artery disease wins expanded indication from FDA. Article

Pharma News

@FiercePharma: Sanofi's Shantha ready to supply 37 million doses of long-delayed pentavalent. FierceVaccines story | Follow @FiercePharma

@EricPFierce: When it comes to Big Pharma revenues, who's the biggest of them all? Special report | Follow @EricPFierce

@CarlyHFierce: Don't forget that there are FOUR regions to vote in today - let's show the oncology drugs some love, shall we? More on FierceMadness | Follow @CarlyHFierce

> Sanofi's diabetes franchise one step closer to U.S. Lyxumia launch. More

> Daiichi shells out $200M-plus to help AstraZeneca launch Movantik. News

> Bristol-Myers chief's last 'paycheck' as CEO is a doozy at $27M. Article

CRO News

> Quintiles taps Google partner Tute Genomics for R&D. Item

> Trial tech outfit Clinical Ink merges with app upstart. News

> Evotec pairs up with Second Genome to gut out some R&D. More

> Catalent shakes up its business with an eye on product launches. Story

> WuXi dives into the CAR-T fray with new plant plans. Article

Vaccines News

> Cancer vaccine maker Aduro files for $86M IPO. Item

> Allergy Therapeutics scores $30M to finish grass allergy vaccine. More

> England to provide GSK MenW vaccine to 3 million teens. News

> GSK to test Ebola jab with booster from Emergent BioSolutions. Report

> More vaccines deals for Pfizer? It wouldn't say no, exec says. Story

Pharma Manufacturing News

> Puerto Rico manufacturing base to grow with AbbVie expansion. More

> Kite Pharma adds manufacturing assets with T-Cell Factory acquisition. Item

> India's Micro Labs recalls drugs made at banned plant. Report

> Wockhardt says FDA impressed by the strides it made at a banned plant. Article

> Lawsuit would force FDA to ban or label wheat gluten as ingredient. Story

Pharma Asia News

> U.S.-based lawsuits pile up for Japan's Olympus in superbug case. Item

> Indonesia drug industry investment lags despite universal insurance program. Article

> Daiichi Sankyo pays $200M to AstraZeneca for Movantik U.S. sales rights. Story

> U.S. FDA softens approach in meetings with Indian regulators. Report

> India's Wockhardt, Granules, suggest recent FDA inspections went well. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.